Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal female, between 18 and 49 years of age, inclusive, at the time of signing consent.~2. Clinical diagnosis of endometriosis (laparoscopy or laparotomy) performed within 10 years of entry into Washout (if applicable) or Screening.~3. Agrees to use required birth control methods during the entire length of participation in the study.~4. Subject has a Composite Pelvic Signs and Symptoms Score total score of ≥ 6 at Screening with a score of at least 2 for dysmenorrhea AND at least 2 for non-menstrual pelvic pain. 5. Subjects must have at least two menstrual cycles 24 to 38 days within the Screening Period, prior to Day 1~Exclusion Criteria:~1. Subject is pregnant or breast feeding or is planning a pregnancy within the next 24 months or is less than 6 months postpartum, post-abortion, or post-pregnancy at the time of entry into the Screening Period.~2. Subject has a history of previous non-response to Gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, Depot Medroxyprogesterone Acetate, or aromatase inhibitors as assessed by subject report of no improvement in dysmenorrhea or non-menstrual pelvic pain (subject report of partial response to or side effects from these agents is not exclusionary).~3. Subject has chronic pelvic pain that is not caused by endometriosis that requires chronic analgesic or other chronic therapy, or that would interfere with the assessment of endometriosis related pain.~4. Clinically significant gynecologic condition identified on Screening transvaginal ultrasound or endometrial biopsy.~5. Subject has a history of osteoporosis or other metabolic bone disease.~6. Subject has a current history of undiagnosed abnormal genital bleeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix 150 mg QD (Type: EXPERIMENTAL): Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
- Elagolix 200 mg BID (Type: EXPERIMENTAL): Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
- Placebo (Type: PLACEBO_COMPARATOR): Placebo BID for the 6-month Treatment Period

Based on this trial design, predict the completion outcome and termination type (if applicable).